TheraCryf PLC
TCF
Company Profile
Business description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
9
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,796.00 | 23.70 | -0.27% |
| CAC 40 | 7,775.68 | 0.22 | -0.00% |
| DAX 40 | 23,850.50 | 98.40 | -0.41% |
| Dow JONES (US) | 42,834.51 | 31.26 | -0.07% |
| FTSE 100 | 8,883.76 | 19.41 | 0.22% |
| HKSE | 24,035.38 | 331.56 | -1.36% |
| NASDAQ | 19,637.63 | 21.75 | 0.11% |
| Nikkei 225 | 38,173.09 | 248.10 | -0.65% |
| NZX 50 Index | 12,649.10 | 43.17 | 0.34% |
| S&P 500 | 6,031.74 | 9.50 | 0.16% |
| S&P/ASX 200 | 8,565.10 | 27.00 | -0.31% |
| SSE Composite Index | 3,402.66 | 0.34 | 0.01% |